Publications

RX-3117 promotes epigenetic effects in cancer cells through enhanced degradation of DNMT1

PCS3117

Dzjemma Sarkisjan, Marc Van Dijk, Ferry Pronk, Rosan Kuin, Btissame el Hassouni, Young B. Lee, Deog J. Kim, Daan P. Geerke, Godefridus J. Peters

View Publication

Phenotyping Pancreatic Cancer CTCs As Biomarkers For RX-3117 Clinical Trials

PCS3117

D.J. Kim, Jie Yang, Weiguo Wu, Darren W. Davis & Andrew Eisen Rexahn Pharmaceuticals, Inc. and Precision for Medicine, Houston, TX

Unusual mechanism of resistance to the novel cytidine analog fluorocyclopentenylcytosine (RX-3117)

PCS3117

Godefridus J Peters, Dzjemma Sarkisjan, Btissame El Hassouni, Richard J Honeywell, Joris R Julsing, Beatrice Balboni, Giulia Mantini, Daniel J de Klerk, Safet Zekanovic, Kees Smid, Elisa Giovannetti, Young B Lee, Deog J Kim

View Publication

Preliminary phase 1 data of single agent RX-3117, an oral antimetabolite nucleoside

PCS3117

Drew Rasco, Christine Peterson, and Ely Benaim, South Texas Accelerated Therapeutics, San Antonio, TX, Rexahn Pharmaceuticals Inc., Rockville, MD

View Publication